Biomolecular condensates, membrane-less entities arising from liquid–liquid phase
separation, hold dichotomous roles in health and disease. Alongside their physiological …

Since its discovery over 35 years ago, MDM2 has emerged as an attractive target for the
development of cancer therapy. MDM2's activities extend from carcinogenesis to immunity to …

Protein-protein interactions are fundamental to the formation of intricate interaction networks
and the assembly of multisubunit protein complexes that represent the functional …

Multicomponent reactions (MCRs) are one-pot reactions employing more than two starting
materials, for example, 3, 4,..., 7, where most of the atoms of the starting materials are …

The MDM2 and MDMX (also known as HDMX and MDM4) proteins are deregulated in many
human cancers and exert their oncogenic activity predominantly by inhibiting the p53 tumour …

Design of small-molecule inhibitors (MDM2 inhibitors) to block the MDM2–p53 protein–
protein interaction has been pursued as a new cancer therapeutic strategy. In recent years …

MDM2 and MDMX are the primary negative regulators of p53, which under normal
conditions maintain low intracellular levels of p53 by targeting it to the proteasome for rapid …

Restoration of p53 activity by inhibition of the p53–MDM2 interaction has been considered
an attractive approach for cancer treatment. However, the hydrophobic protein–protein …

Disruption of the MDM2-p53 protein-protein interaction by small-molecule inhibitors has
been highly pursued by many academic laboratories and pharmaceutical companies as a …

For more than 25 years, MDM2 and its homolog MDMX (also known as MDM4) have been
shown to exert oncogenic activity. These two proteins are best understood as negative …